Structural Characterization of Human Cytochrome P450 2C19: Active Site Differences Between P450s 2C8, 2C9, and 2C19

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2012 Nov 3

PMID 23118231

Citations 39

Authors

R Leila Reynald

Stefaan Sansen

C David Stout

Eric F Johnson

Affiliations

Soon will be listed here.

Abstract

To identify the structural features underlying the distinct substrate and inhibitor profiles of P450 2C19 relative to the closely related human enzymes, P450s 2C8 and 2C9, the atomic structure (Protein Data Bank code 4GQS) of cytochrome P450 2C19 complexed with the inhibitor (2-methyl-1-benzofuran-3-yl)-(4-hydroxy-3,5-dimethylphenyl)methanone (Protein Data Bank chemical component 0XV) was determined to 2.87 Å resolution by x-ray crystallography. The conformation of the peptide backbone of P450 2C19 is most similar to that of P450 2C8, but the substrate-binding cavity of P450 2C8 is much larger than that of P450 2C19 due to differences in the amino acid residues that form the substrate-binding cavities of the two enzymes. In contrast, the substrate-binding cavity of P450 2C19 is much more similar in size to that of the structure of the P450 2C9 flurbiprofen complex than to that of a modified P450 2C9 or that of P450 2C8. The cavities of the P450 2C19 0XV complex and the P450 2C9 flurbiprofen complex differ, however, because the helix B-C loops of the two enzymes are dissimilar. These conformational differences reflect the effects of adjacent structural elements that interact with the B-C loops and that differ between the two enzymes. The availability of a structure for 2C19 will facilitate computational approaches for predictions of substrate and inhibitor binding to this enzyme.

Citing Articles

Deep mutational scanning of CYP2C19 in human cells reveals a substrate specificity-abundance tradeoff.

Boyle G, Sitko K, Galloway J, Haddox H, Bianchi A, Dixon A Genetics. 2024; 228(3).

PMID: 39319420 PMC: 11538415. DOI: 10.1093/genetics/iyae156.

Investigation of studies for cytochrome P450 isoforms specificity.

Wei Y, Palazzolo L, Ben Mariem O, Bianchi D, Laurenzi T, Guerrini U Comput Struct Biotechnol J. 2024; 23:3090-3103.

PMID: 39188968 PMC: 11347072. DOI: 10.1016/j.csbj.2024.08.002.

Computational Binding Study Hints at Ecdysone 20-Mono-Oxygenase as the Hitherto Unknown Target for Ring C-Seco Limonoid-Type Insecticides.

Ramirez R, Buendia-Corona R, Perez-Xochipa I, Scior T Molecules. 2024; 29(7).

PMID: 38611907 PMC: 11013123. DOI: 10.3390/molecules29071628.

*2/*2 Genotype is a Risk Factor for Multi-Site Arteriosclerosis: A Hospital-Based Cohort Study.

Xie J, Pan T, Luo W, Zhang S, Fang Y, Xu Z Int J Gen Med. 2023; 16:5139-5146.

PMID: 37954650 PMC: 10637229. DOI: 10.2147/IJGM.S437251.

Melatonin Activation by Human Cytochrome P450 Enzymes: A Comparison between Different Isozymes.

Mokkawes T, De Visser T, Cao Y, de Visser S Molecules. 2023; 28(19).

PMID: 37836804 PMC: 10574541. DOI: 10.3390/molecules28196961.

References

Jung F, Griffin K, Song W, Richardson T, Yang M, Johnson E . Identification of amino acid substitutions that confer a high affinity for sulfaphenazole binding and a high catalytic efficiency for warfarin metabolism to P450 2C19. Biochemistry. 1998; 37(46):16270-9. DOI: 10.1021/bi981704c. View

Williams P, Cosme J, Ward A, Angove H, Vinkovic D, Jhoti H . Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature. 2003; 424(6947):464-8. DOI: 10.1038/nature01862. View

Spina E, Santoro V, DArrigo C . Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther. 2008; 30(7):1206-27. DOI: 10.1016/s0149-2918(08)80047-1. View

Ingelman-Sundberg M, Sim S, Gomez A, Rodriguez-Antona C . Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007; 116(3):496-526. DOI: 10.1016/j.pharmthera.2007.09.004. View

Wang H, An N, Wang H, Gao Y, Liu D, Bian T . Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation. Drug Metab Dispos. 2011; 39(5):830-7. DOI: 10.1124/dmd.110.037549. View

Goldstein J, Faletto M, Sullivan T, Kitareewan S, Raucy J, Lasker J . Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. Biochemistry. 1994; 33(7):1743-52. DOI: 10.1021/bi00173a017. View

Tiroch K, Sibbing D, Koch W, Roosen-Runge T, Mehilli J, Schomig A . Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J. 2010; 160(3):506-12. DOI: 10.1016/j.ahj.2010.06.039. View

Dickmann L, Locuson C, Jones J, Rettie A . Differential roles of Arg97, Asp293, and Arg108 in enzyme stability and substrate specificity of CYP2C9. Mol Pharmacol. 2004; 65(4):842-50. DOI: 10.1124/mol.65.4.842. View

Dansette P, Rosi J, Bertho G, Mansuy D . Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer. Chem Res Toxicol. 2011; 25(2):348-56. DOI: 10.1021/tx2004085. View

10.

Cuisset T, Morange P, Alessi M . Recent advances in the pharmacogenetics of clopidogrel. Hum Genet. 2011; 131(5):653-64. DOI: 10.1007/s00439-011-1130-6. View

11.

Cosme J, Johnson E . Engineering microsomal cytochrome P450 2C5 to be a soluble, monomeric enzyme. Mutations that alter aggregation, phospholipid dependence of catalysis, and membrane binding. J Biol Chem. 2000; 275(4):2545-53. DOI: 10.1074/jbc.275.4.2545. View

12.

McCoy A, Grosse-Kunstleve R, Storoni L, Read R . Likelihood-enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr. 2005; 61(Pt 4):458-64. DOI: 10.1107/S0907444905001617. View

13.

Mosher C, Tai G, Rettie A . CYP2C9 amino acid residues influencing phenytoin turnover and metabolite regio- and stereochemistry. J Pharmacol Exp Ther. 2009; 329(3):938-44. PMC: 2683772. DOI: 10.1124/jpet.109.150706. View

14.

Locuson 2nd C, Suzuki H, Rettie A, Jones J . Charge and substituent effects on affinity and metabolism of benzbromarone-based CYP2C19 inhibitors. J Med Chem. 2004; 47(27):6768-76. DOI: 10.1021/jm049605m. View

15.

Wada Y, Mitsuda M, Ishihara Y, Watanabe M, Iwasaki M, Asahi S . Important amino acid residues that confer CYP2C19 selective activity to CYP2C9. J Biochem. 2008; 144(3):323-33. DOI: 10.1093/jb/mvn070. View

16.

Dansette P, Libraire J, Bertho G, Mansuy D . Metabolic oxidative cleavage of thioesters: evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel. Chem Res Toxicol. 2009; 22(2):369-73. DOI: 10.1021/tx8004828. View

17.

Omura T, Sato R . THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. II. SOLUBILIZATION, PURIFICATION, AND PROPERTIES. J Biol Chem. 1964; 239:2379-85. View

18.

Richardson T, Jung F, Griffin K, Wester M, Raucy J, Kemper B . A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in Escherichia coli. Arch Biochem Biophys. 1995; 323(1):87-96. DOI: 10.1006/abbi.1995.0013. View

19.

Schoch G, Yano J, Wester M, Griffin K, Stout C, Johnson E . Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. J Biol Chem. 2003; 279(10):9497-503. DOI: 10.1074/jbc.M312516200. View

20.

Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N . Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2008; 360(4):363-75. DOI: 10.1056/NEJMoa0808227. View